Global Retirement Partners LLC increased its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report) by 366.6% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 1,773 shares of the company’s stock after purchasing an additional 1,393 shares during the quarter. Global Retirement Partners LLC’s holdings in Medpace were worth $996,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also made changes to their positions in the business. BOKF NA boosted its position in shares of Medpace by 0.8% in the 3rd quarter. BOKF NA now owns 2,542 shares of the company’s stock worth $1,307,000 after buying an additional 20 shares in the last quarter. Valeo Financial Advisors LLC boosted its position in shares of Medpace by 5.0% in the 4th quarter. Valeo Financial Advisors LLC now owns 444 shares of the company’s stock worth $249,000 after buying an additional 21 shares in the last quarter. HighPoint Advisor Group LLC boosted its position in shares of Medpace by 2.8% in the 3rd quarter. HighPoint Advisor Group LLC now owns 810 shares of the company’s stock worth $416,000 after buying an additional 22 shares in the last quarter. Kaufman Rossin Wealth LLC lifted its holdings in Medpace by 3.4% in the 4th quarter. Kaufman Rossin Wealth LLC now owns 795 shares of the company’s stock valued at $447,000 after purchasing an additional 26 shares in the last quarter. Finally, Whittier Trust Co. of Nevada Inc. lifted its holdings in Medpace by 35.1% in the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 104 shares of the company’s stock valued at $55,000 after purchasing an additional 27 shares in the last quarter. 77.98% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Ratings Changes
A number of research firms have issued reports on MEDP. Wall Street Zen lowered shares of Medpace from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. Truist Financial reduced their target price on shares of Medpace from $555.00 to $539.00 and set a “hold” rating on the stock in a report on Wednesday, February 11th. Barclays reduced their target price on shares of Medpace from $500.00 to $450.00 and set an “equal weight” rating on the stock in a report on Friday, April 24th. Robert W. Baird reduced their target price on shares of Medpace from $565.00 to $477.00 and set an “outperform” rating on the stock in a report on Friday, April 24th. Finally, Jefferies Financial Group upgraded shares of Medpace from a “hold” rating to a “buy” rating and set a $560.00 target price on the stock in a report on Friday, February 13th. Four investment analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Medpace has an average rating of “Hold” and a consensus target price of $467.08.
Insider Transactions at Medpace
In related news, President Jesse J. Geiger sold 31,707 shares of the stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $455.30, for a total transaction of $14,436,197.10. Following the completion of the sale, the president owned 15,000 shares of the company’s stock, valued at approximately $6,829,500. This represents a 67.88% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 20.50% of the company’s stock.
Medpace Price Performance
Shares of MEDP stock opened at $432.80 on Tuesday. The firm has a market cap of $12.36 billion, a P/E ratio of 27.20, a PEG ratio of 2.20 and a beta of 1.19. Medpace Holdings, Inc. has a 1-year low of $287.17 and a 1-year high of $628.92. The firm’s 50-day simple moving average is $458.70 and its 200-day simple moving average is $517.79.
Medpace (NASDAQ:MEDP – Get Free Report) last announced its quarterly earnings data on Wednesday, April 22nd. The company reported $4.28 earnings per share for the quarter, topping the consensus estimate of $3.74 by $0.54. The business had revenue of $706.60 million for the quarter, compared to analyst estimates of $697.82 million. Medpace had a net margin of 17.19% and a return on equity of 120.89%. The company’s revenue was up 26.5% on a year-over-year basis. During the same period in the prior year, the firm posted $3.67 EPS. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. Analysts expect that Medpace Holdings, Inc. will post 17.04 earnings per share for the current fiscal year.
Medpace Company Profile
Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.
Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.
Featured Stories
- Five stocks we like better than Medpace
- SpaceX Gets the Attention, But These 4 Stocks Could Get the Returns
- Microsoft Stock Discount May Be Ending as AI Catalysts Build
- Apparel Earnings Winners and Losers: Ralph Lauren Takes Off
- Why Walmart, Target and TJX Got Such Different Reactions After Earnings
Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report).
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.
